Literature DB >> 25295642

H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study.

Peter J Leary1, R Graham Barr, David A Bluemke, Michael R Bristow, Richard A Kronmal, Joao A Lima, David D Ralph, Corey E Ventetuolo, Steven M Kawut.   

Abstract

RATIONALE: H2 receptor antagonist (H2RA) use is common and may act directly on the heart through myocardial H2 receptors or indirectly through changes in pulmonary vascular resistance.
OBJECTIVES: To determine the relationship between histamine H2RA use and right ventricular (RV) morphology.
METHODS: We studied 4,122 participants in the Multi-Ethnic Study of Atherosclerosis without clinical cardiovascular disease who had magnetic resonance imaging assessment of RV morphology and ascertainment of medication use. Multivariable linear regression estimated cross-sectional associations between H2RA use and RV morphology after adjusting for demographics, anthropometrics, smoking status, diabetes mellitus, and hypertension. Further adjustments for co-medication use, left ventricular parameters, lung structure and function, renal function, or inflammatory markers were considered in separate models. Analyses in a subcohort restricted to H2RA or proton pump inhibitor users accounted for confounding by the indication of gastroesophageal reflux disease.
MEASUREMENTS AND MAIN RESULTS: H2RA use was associated with lower RV mass (-0.7 g; 95% confidence interval, -1.2 to -0.2 g; P = 0.004) and smaller RV end-diastolic volume (-4.2 ml; 95% confidence interval, -7.2 to -1.2 ml; P = 0.006). This relationship was unchanged with adjustment for co-medication use, lung structure and function, renal function, and inflammation. The relationship with RV mass was independent of left ventricular mass. Results were similar in the smaller cohort restricted to proton pump inhibitor and H2RA users.
CONCLUSIONS: H2RA use was associated with lower RV mass and smaller RV end-diastolic volume. Additional study of histamine and H2 receptors in cardiopulmonary diseases affecting the RV may have direct clinical relevance.

Entities:  

Keywords:  heart ventricles; histamine; histamine H2 receptors; pulmonary hypertension

Mesh:

Substances:

Year:  2014        PMID: 25295642      PMCID: PMC4298988          DOI: 10.1513/AnnalsATS.201407-344OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  35 in total

1.  Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension.

Authors:  Beatrijs Bartelds; Rosa Laura E van Loon; Saffloer Mohaupt; Hans Wijnberg; Michael G Dickinson; Bibiche Boersma; Janny Takens; Mirjam van Albada; Rolf M F Berger
Journal:  Chest       Date:  2011-09-22       Impact factor: 9.410

2.  Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.

Authors:  Jiyoong Kim; Akiko Ogai; Satoshi Nakatani; Kazuhiko Hashimura; Hideaki Kanzaki; Kazuo Komamura; Masanori Asakura; Hiroshi Asanuma; Soichiro Kitamura; Hitonobu Tomoike; Masafumi Kitakaze
Journal:  J Am Coll Cardiol       Date:  2006-09-14       Impact factor: 24.094

Review 3.  Blood borne hormones in a cross-talk between peripheral and brain mechanisms regulating blood pressure, the role of circumventricular organs.

Authors:  Marcin Ufnal; Janusz Skrzypecki
Journal:  Neuropeptides       Date:  2014-01-22       Impact factor: 3.286

4.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

Review 5.  Histamine and the human heart: the other receptor system.

Authors:  M R Bristow; R Ginsburg; D C Harrison
Journal:  Am J Cardiol       Date:  1982-01       Impact factor: 2.778

6.  Mast cell activation by fibrinogen-related homologous c-terminal peptides (haptides) modulates systemic blood pressure.

Authors:  Maamoun Basheer; Herzl Schwalb; Maoz Nesher; Dan Gilon; Irit Shefler; Yoseph A Mekori; Oz M Shapira; Raphael Gorodetsky
Journal:  J Allergy Clin Immunol       Date:  2010-09-15       Impact factor: 10.793

7.  Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity.

Authors:  Shunsuke Natori; Shenghan Lai; J Paul Finn; Antoinette S Gomes; W Gregory Hundley; Michael Jerosch-Herold; Gregory Pearson; Shantanu Sinha; Andrew Arai; Joao A C Lima; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

8.  Histamine induced pulmonary vasodilatation in the rat: site of action and changes in chronic hypoxia.

Authors:  P C Russell; C E Wright; G R Barer; P Howard
Journal:  Eur Respir J       Date:  1994-06       Impact factor: 16.671

9.  Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans.

Authors:  Naoyuki Matsuda; Subrina Jesmin; Yoshika Takahashi; Eiichiro Hatta; Masanobu Kobayashi; Kazuto Matsuyama; Nozomi Kawakami; Ichiro Sakuma; Satoshi Gando; Hiyoyuki Fukui; Yuichi Hattori; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2004-01-29       Impact factor: 4.030

10.  Relationship of CRP, IL-6, and fibrinogen with right ventricular structure and function: the MESA-Right Ventricle Study.

Authors:  Michael O Harhay; Russell P Tracy; Emilia Bagiella; R Graham Barr; Diane Pinder; W Gregory Hundley; David A Bluemke; Richard A Kronmal; Joao A C Lima; Steven M Kawut
Journal:  Int J Cardiol       Date:  2013-08-09       Impact factor: 4.164

View more
  6 in total

1.  H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program.

Authors:  Peter J Leary; Edward Hess; Anna E Barón; Kelley R Branch; Gaurav Choudhary; Catherine L Hough; Bradley A Maron; David D Ralph; John J Ryan; Ryan J Tedford; Noel S Weiss; Roham T Zamanian; Tim Lahm
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

2.  Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.

Authors:  Peter J Leary; Ryan J Tedford; David A Bluemke; Michael R Bristow; Susan R Heckbert; Steven M Kawut; Eric V Krieger; Joao A Lima; Carolina S Masri; David D Ralph; Steven Shea; Noel S Weiss; Richard A Kronmal
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

Review 3.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 4.  Histamine receptors in heart failure.

Authors:  Scott P Levick
Journal:  Heart Fail Rev       Date:  2021-10-08       Impact factor: 4.654

5.  Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial).

Authors:  Peter J Leary; Richard A Kronmal; David A Bluemke; Peter M Buttrick; Kenneth L Jones; David P Kao; Steven M Kawut; Eric V Krieger; Joao A Lima; Wayne Minobe; David D Ralph; Ryan J Tedford; Noel S Weiss; Michael R Bristow
Journal:  Am J Cardiol       Date:  2017-10-20       Impact factor: 2.778

Review 6.  The right treatment for the right ventricle.

Authors:  Joanne A Groeneveldt; Frances S de Man; Berend E Westerhof
Journal:  Curr Opin Pulm Med       Date:  2019-09       Impact factor: 3.155

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.